CTRI/2021/09/036193招募中2 期
A Prospective, Randomized, Parallel Group,Open Label, Active Controlled Clinical Study toEvaluate the Efficacy and Safety of Safoof-iMuhazzil and Arq-i Zeera in the Management ofDyslipidaemia
ational Research Institute of Unani Medicine for Skin Disorders0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(i). Participants of any gender aged 30 t0 60 years. (ii) Participants having any one or more of the following lipid abnormalities in blood: a. Total Cholestrol more than or equal to 200 mg/dl b. LDL Cholesterol more than or equal to 130 mg/dl c. HDL Cholesterol less than 40 mg/dl d. Serum Triglycerides 150-400 mg/dl (iii) Body Mass Index 23-40 kg/m2
排除标准
- •i. Participants aged <30 and >60 years.
- •ii. Serum Triglyceride <150 mg/dL or >400 mg/dL
- •iii. Body Mass Index (BMI) <23 or >40 kg/m2
- •iv. Participants having hypertension & diabetes
- •v. Significant Pulmonary/ Cardiovascular/ Hepatorenal
- •Dysfunction
- •vi. Known cases of malignancy, HIV infection,
- •vii. Any other clinical condition that in the opinion
- •of the investigator would compromise the
- •patientâ??s safety or successful participation in the
- •viii. Pregnancy and Lactation
- •ix. Known allergy, sensitivity or intolerance to the
- •study drug or any of its ingredients.
- •x. Participants with active alcohol intake and/or
- •drug abuse.
- •xi. Participants not willing to sign the ICF and to
- •attend treatment schedule regularly
研究者
相似试验
招募中
不适用
Bacterial contamination of regular contact lens cases during daily wear of marketed and investigational contact lenses.ACTRN12609000067279CIBA VISIO80
进行中（未招募）
1 期
IMU-838 and Oseltamivir in treatment of Novel Coronavirus (COVID-19)Sars-Cov-2EUCTR2020-001805-21-GBniversity Hospital Coventry & Warwickshire120
招募中
4 期
A Study to Evaluate the Efficacy and Safety of fixed dose combination of Etoricoxib(60mg) and Thiocolchicoside (4mg) in patients with Low Back Pain.CTRI/2022/07/043690MANKIND PHARMA LTD
尚未招募
2 期
The Efficacy and Safety of Habb-i Dard-i Mafasil in Wajaâ?? al-MafÄ?á¹£il (Osteoarthritis)CTRI/2021/08/036008ational research institute of Unani medicine for skin disorders
尚未招募
2 期
Efficacy of a Unani formulation in DyslipidaemiaCTRI/2023/10/059299ational Research Institute of Unani Medicine For Skin Disorders